Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM)

AFTX-201 is designed using Affinia's proprietary capsid engineered for efficient cardiac transduction at doses that are 5-10-fold lower than doses of gene therapies using conventional capsids WALTHAM, ...
Nasdaq

OKYO Pharma Files Application for Fast Track Designation for Urcosimod in Treatment of Neuropathic Corneal Pain

OKYO Pharma Limited has filed for Fast Track designation with the U.S. FDA for its drug urcosimod, aimed at treating neuropathic corneal pain, a painful eye condition currently lacking an FDA-approved ...
Monthly Prescribing Reference

OKYO Pharma Seeks Fast Track for Urcosimod in Neuropathic Corneal Pain

Urcosimod is currently being evaluated in a phase 2 trial evaluating it's efficacy and safety in adults with neuropathic corneal pain. OKYO Pharma has filed a Fast Track designation application with ...
Seeking Alpha

BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder

ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related ...